In the TRIUMPH-1 Phase 3 trial, participants on the maximum dose of retatrutide (12 mg) lost an average of 28.3% of their body weight after 80 weeks, and up to 30.3% after 104 weeks in the study extension
Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis
Symptoms, medical history, physical examination, and overall health goals all factor into determining the best treatment approach
Nausea is particularly common, especially when starting treatment or when your dose is increased
Let's start by understanding exactly what allulose is, and I'll never forget when I first learned about this compound, because I saw it as an ingredient on, I think, some sort of Quest bar